Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
about
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancerRole of ABL family kinases in cancer: from leukaemia to solid tumoursMalignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signalingTargeting the PDGF signaling pathway in tumor treatmentTranscriptional analysis reveals gender-specific changes in the aging of the human immune system.Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studiesNew cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancerSrc Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptationsThe Emerging Role of ABL Kinases in Solid Tumors.Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast CancerMechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation.Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors.The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
P2860
Q24658633-DA1AA32A-D30A-4E62-9C0D-014985C87E87Q28396643-3358301E-ABA6-491B-895B-54DAC7BC6F40Q34309316-CC1D48BC-2875-4543-8759-B3C7FD531778Q34393461-DAE37BA1-7FD7-4925-99F7-DA77B5F2E2C2Q34776449-C2D80E93-5FB6-44EE-A87D-74E81D446217Q35000307-8316D920-AB97-4F0C-8FF4-3454C1EAAF88Q35016088-03DEFDC4-81CF-49ED-A153-A61DCB557E1AQ35168124-75D6E60A-F5EC-48EC-96C2-408E727B87F3Q35521281-C51CDC25-1EEC-4D43-BD72-B61CFE467D07Q36053869-6D4FFCC5-3E4E-40B5-8608-6E27A7E7B174Q36317659-5A6F76AC-674D-4F54-B5CD-6A219D30D99EQ36347666-EAA96D2C-99CC-43E4-94E4-3EBF8B6CF1C1Q36447475-AE577E94-4411-48BB-933E-779D1313EA3FQ36589865-74709549-D9CC-41D8-97E7-9D4651D5A05BQ36947802-6847F22F-BE74-421A-ABEB-52337DD8C214Q38193533-98B5F549-ED66-4FAE-81ED-9E61A21529F0Q38543837-56CF621C-A807-44F3-9316-2BBF79BF7358Q42101498-B264C28D-78DC-4975-B6F9-B2FB7E138B3DQ52673059-670C8650-2413-40E2-97F7-22080B8579A4Q54186456-4B7884A0-2232-4635-96DF-00158C52DCA2Q55479657-AD7C492D-B4C9-4174-AE22-6548CD2CF425
P2860
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Preclinical and clinical studi ...... e resistance in breast cancer.
@ast
Preclinical and clinical studi ...... e resistance in breast cancer.
@en
type
label
Preclinical and clinical studi ...... e resistance in breast cancer.
@ast
Preclinical and clinical studi ...... e resistance in breast cancer.
@en
prefLabel
Preclinical and clinical studi ...... e resistance in breast cancer.
@ast
Preclinical and clinical studi ...... e resistance in breast cancer.
@en
P2093
P2860
P356
P1476
Preclinical and clinical studi ...... ne resistance in breast cancer
@en
P2093
Lesley-Ann Martin
Marion T Weigel
Mitch Dowsett
Zara Ghazoui
P2860
P2888
P356
10.1186/BCR3191
P577
2012-05-18T00:00:00Z
P5875
P6179
1032552795